Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;40(9):2041-2045.
doi: 10.1007/s10096-021-04243-0. Epub 2021 Apr 15.

The ID NOW COVID-19, a high-speed high-performance assay

Eric Farfour  1 , M Asso-Bonnet  2 , M Vasse  2 ; SARS-CoV-2 Foch Hospital study group
Collaborators, Affiliations

The ID NOW COVID-19, a high-speed high-performance assay

Eric Farfour et al. Eur J Clin Microbiol Infect Dis. 2021 Sep.

Abstract

The ID NOW COVID-19 assay is a promising tool for the rapid identification of COVID-19 patients. However, its performances were questioned. We evaluate the ID NOW COVID-19 in comparison to a reference RT-PCR using a collection of 48 fresh nasopharyngeal swabs sampled on universal transport media (UTM). Only 2 false negatives of the ID NOW COVID-19 were identified. They display PCR cycle threshold values of 37.5 and 39.2. The positive percent agreement and the negative percent agreement were 94.9% and 100%, respectively. The Kappa value was 0.88. The ID NOW COVID-19 combines high-speed and accurate processing. Using UTM, the ID NOW COVID-19 could be repeated in the case of invalid result. Further analyses, such as screening of genetic variants or genome sequencing, could also be performed with the same sample. As for all tests, the results should be interpreted according to clinical and epidemiological context.

Keywords: COVID-19; Isothermal amplification; LAMP; NEAR; RT-PCR; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Results of the ID NOW COVID-19 according to the class of CT value of the reference RT-PCR
See this image and copyright information in PMC

References

    1. Farfour E, Lesprit P, Visseaux B, Pascreau T, Jolly E, Houhou N, et al. The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis? Eur J Clin Microbiol Infect Dis. 2020;39(10):1997–2000. doi: 10.1007/s10096-020-03930-8. - DOI - PMC - PubMed
    1. Farfour E, Jolly E, Pascreau T, Asso-Bonnet M, Mazaux L, Vasse M (2020) SARS-CoV-2 RT-PCR: at least 2 viral targets are needed. Infect Dis (Lond) 52(8):583–584. 10.1080/23744235.2020.1769178 - PubMed
    1. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S et al. (2021) Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 3:CD013705. 10.1002/14651858.CD013705 - PMC - PubMed
    1. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol. 2020;129:104455. doi: 10.1016/j.jcv.2020.104455. - DOI - PMC - PubMed
    1. Farfour E, Roux A, Ballester M, Gagneur L, Renaux C, Jolly E, et al. Improved performances of the second generation of the ID NOW Influenza A&B 2® and comparison with the GeneXpert®. Eur J Clin Microbiol Infect Dis. 2020;39(9):1681–1686. doi: 10.1007/s10096-020-03905-9. - DOI - PubMed

Publication types

MeSH terms